---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007875"
form_type: "8-K"
ticker: "SNGX"
cik: "0000812796"
company_name: "SOLIGENIX, INC."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T02:02:46.623877+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Soligenix appoints Timothy Coté to board, expands size to six

## Summary
- Board expanded from 5 to 6; Timothy R. Coté, M.D. appointed as director, term expiring at 2023 annual meeting.
- Dr. Coté granted fully-vested non-qualified stock option for 15,000 shares at $1.42 per share, plus $35,000 annual cash.
- Former FDA OOPD director, implementing Orphan Drug Act; founded Coté Orphan sold to IQVIA for $20M.
- Also CEO of Silk Road Therapeutics; Soligenix recently acquired exclusive option to its PTX topical for Behçet's Disease.

## SEC filing metadata
- accession: 0001558370-23-007875
- form_type: 8-K
- ticker: SNGX
- cik: 0000812796
- company_name: SOLIGENIX, INC.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/812796/000155837023007875/0001558370-23-007875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/812796/000155837023007875/sngx-20230503x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007875
- JSON: https://secwatch.observer/filing/0001558370-23-007875.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007875.txt

## Key facts
- Executive change
  Timothy R. Coté was appointed as director at SOLIGENIX, INC..
  - Action: appointed
  - Role: director
  source text: On May 3, 2023, the Board of Directors (the “Board”) of Soligenix, Inc. (the “Company”) increased the size of the Board from five to six members and appointed Timothy R. Coté, MD, MPH as a director, with an initial term expiring at the Company’s 2023 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/812796/000155837023007875/0001558370-23-007875-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.